Endurant Capital Management LP purchased a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 4,596 shares of the biopharmaceutical company’s stock, valued at approximately $1,092,000. A number of […]